习题及解答_百度文库
您的浏览器Javascript被禁用，需开启后体验完整功能，
享专业文档下载特权
&赠共享文档下载特权
&10W篇文档免费专享
&每天抽奖多种福利
两大类热门资源免费畅读
续费一年阅读会员，立省24元！
习题及解答
阅读已结束，下载本文需要
定制HR最喜欢的简历
下载文档到电脑，同时保存到云知识，更方便管理
加入VIP
还剩1页未读，
定制HR最喜欢的简历
你可能喜欢若函数f(x)=㏒2 (x+1)且a&b&c&0,则f(a)/a,f(b)/b,f(c)/c的大小关系？_百度知道
若函数f(x)=㏒2 (x+1)且a&b&c&0,则f(a)/a,f(b)/b,f(c)/c的大小关系？
答题抽奖
首次认真答题后
即可获得3次抽奖机会，100%中奖。
昏月橘光知道合伙人
采纳数：19
获赞数：19
跟c++无关吧g(x)=f(x)/x=log2(x+1)/2g'(x)=(x/(x+1)-ln(x+1))/(ln2*x^2)令h(x)=x-(x+1)ln(x+1)，h(0)=0，h'(x)=-ln(x+1)，x&0时h'(x)&0，故h(x)x&0时递减，h(x)&0所以x&0时g'(x)&0，g(x)x&0时递减所以f(a)/a&f(b)/b&f(c)/c
zll890221知道合伙人
获赞数：488
擅长：暂未定制
设g(x)=f(x)/x=log2(x+1)/x
∴g'(x)=(x-(x+1)ln(x+1))/ln2x²(x+1)
∵x-(x+1)ln(x+1)的导数为：-ln(x+1) 又x＞0 ∴-ln(x+1)＜0∴x-(x+1)ln(x+1)＜0∴g'(x)＜0
∴f(a)/a＜f(b)/b＜f(c)/c
为你推荐：
其他类似问题
个人、企业类
违法有害信息,请在下方选择后提交
色情、暴力
我们会通过消息、邮箱等方式尽快将举报结果通知您。（理科）已知圆C：x2+y2=1和点Q（2，0），动点M到圆C的切线长与|MQ|的比等于常数λ（λ＞0），求动点M的_数学_蒙上作业网
当前位置：&>&&>& > （理科）已知圆C：x2+y2=1和点Q（2，0），动点M到圆C的切线长与|MQ|的比等于常数λ（λ＞0），求动点M的
（理科）已知圆C：x2+y2=1和点Q（2，0），动点M到圆C的切线长与|MQ|的比等于常数λ（λ＞0），求动点M的
解：如图，设MN切圆于N，则动点M组成的集合是P={M||MN|=λ|MQ|}，式中常数λ＞0．因为圆的半径|ON|=1，所以|MN|2=|MO|2-|ON|2=|MO|2-1．设点M的坐标为（x，y），则x2+y2?1=λ(x?2)2+y2整理得（λ2-1）（x2+y2）-4λ2x+（1+4λ2）=0．经检验，坐标适合这个方程的点都属于集合P．故这个方程为所求的轨迹方程．当λ=1时，方程化为x=54，它表示一条直线，该直线与x轴垂直且交x轴于点（54，0），当λ≠1时，方程化为（x-2λ2λ2?1）2+y2=1+3λ2(λ2?1)2它表示圆，该圆圆心的坐标为（2λ2λ2?1，0），半径为1+3λ2|λ2?1|．
话题：&&&&&
本文标题：链接地址：
已知a=5log2 3.4,b=5log4 3.6,c=(1/5)log3 0.3,比大小是否是a=5log以2为底数 3.4在上面 因为底数均大于1 增函数 分别将它们拿给1相比 可比出3.4＞2 3.6＜4 a＞b 将1/5提上去 就是3/10开5次方 肯定比b小 故a＞1 b＜1 c＜b 得 a＞ 已知圆C：x2+y2-4x-14y+45=0．（1）若M是圆C上任意一点，点Q（-2，3），求|MQ|的最大值与最小值．（2）求（1）将圆C：x2+y2-4x-14y+45=0可化为
（x-2）2+（y-7）2=8，
则圆心C（2，7），半径r＝22，
又∵Q（-2，3），
∴|QC|=42，
∴点Q在圆外，
则由|QC|?22≤|MQ|≤|QC|+ 如图,已知A（4,0）B（0,3）C（0，-1）,连接AB,过点C的直线l与AB交于点P....(1) 显然，PB=PC时，P在BC的中垂线上。
BC的中垂线为y = (3-1)/2 = 1
AB的方程为x/4 + y/3 = 1(截距式)
二者联立，可得P的坐标为(8/3, 1)
(2) 直线l与X轴所夹的锐角a=45° 已知圆x^2+y^2+x-6y+m=0与直线x+2y-3=0相交于P、Q两点，O为坐标原点，若OP垂直于OQ,试求m的值。解：圆的方程x² +y² +x-6y+m=0可化为：(x+1/2)² +(y-3)² =37/4 -m
则设圆的圆心为C(-1/2,3)，半径r=√(37/4 -m)
作线段PQ中点M，连结 已知直角坐标平面上点Q（2，0）和圆C：X2+Y2=1.动点M到圆的切线长与MQ的比值分别为1或2时，点M的轨迹方程设M的坐标是(x,y)，
|MC|^2=x^2+y^2
设动点M到圆的切线长为d
d^2=|MC|^2-r^2=x^2+y^2-1
|MQ|^2=(x-2)^2+y^2
当d/MQ=1时，d=MQ，即d^2=|MQ|^2
则：x^2+y^2-1=(x-2 已知M为圆C：x2+y2-4x-14y+45=0上任一点，且点Q（-2，3）．（Ⅰ）若P（a，a+1）在圆C上，求线段PQ的长及（Ⅰ）由点P（a，a+1）在圆C上，
可得a2+（a+1）2-4a-14（a+1）+45=0，所以a=4，P（4，5）．
所以|PQ|＝(4+2)2+(5?3)2＝210，KPQ＝3?5?2?4＝13．（6分）
（Ⅱ）由C：x2+ 已知三角形ABC的三个顶点A（0，0）B（4，8）C（6，-4），向量AM等于-3向量BM，点N在边上AC上，且三角形ABC的面积是四边形MNCB面积的2倍，求直线MN的方程。过程详细点，谢谢AM=3MB,由定比分点公式（高一向量部分的内容），得到M坐标为（3，6）。ABC面积=2AMN面积，而AM=3MB，说明AN=2/3AC,N点坐标为（4，-8/3）MN的直线方程就可以求了 已知a=5S2∧3.4，b=5S4∧3.6，c=（1／5）S3∧0.3，比大小，及做此类题的方法首先我想先问一下：你是向我求助的吗？因为我经常收到求助的东东，也不知道是度娘自己撮合的还是确有其事。然后我说方法吧，比较对数的大小其实就让底数相同再比上面那个数 已知定点A(2,0),Q是曲线C:x2+y2=1上的动点，M为AQ的中点，当Q在曲线C上移动时，求动点M的轨迹方程.A(2,0),Q是曲线C:x2+y2=1上的动点，M为AQ的中点
设M(x,y),则
2x=xA+xQ=2+xQ
2y=yA+yQ=0+yQ
(xQ)^2+(yQ)^2=1
(2x-2)^2+(2y)^2=1
动点 已知圆C:x2+y2+2x-4y+1=0,0为坐标原点，动点P在圆C外，过P作圆C的切线，设切点为M1
圆C:(x+1)^2+(y-2)^2=4
l斜率不存在时，l:x=1与圆C相切
l斜率存在时，设为k，
则l:y-3=k(x-1) 即kx-y+3-k=0
∴C到l的距离d等于半径
∴|-k-2+3-k|/√(k^2+1)=2
解得:k 当A=-3 B=-6 C=3.6 D=-2.5时，计算下列各式（1）ac+bd =（-3）*（3.6）+（-6）*（-2.5）=4.2
（2）a÷b-c÷d =（-3）÷（-6）-（3.6）÷（-2.5）=-0.94
（3）（a-b）÷d=（-3--6）÷（-2.5）=-1.2 已知圆C：x2+y2-4x-14y+45=0．（1）若M是圆（1）将圆C：x2+y2-4x-14y+45=0可化为
（x-2）2+（y-7）2=8，
则圆心C（2，7），半径r＝22，
又∵Q（-2，3），
∴|QC|=42，
∴点Q在圆外，
则由|QC|?22≤|MQ|≤|QC|+ 已知a=5log2 3.4,b=5log4 3.6,c=(1/5)log3 是否是a=5log以2为底数 3.4在上面 因为底数均大于1 增函数 分别将它们拿给1相比 可比出3.4＞2 3.6＜4 a＞b 将1/5提上去 就是3/10开5次方 肯定比b小 故a＞1 b＜1 c＜b 得 a＞ 如图,已知A（4,0）B（0,3）C（0，-1）,连接(1) 显然，PB=PC时，P在BC的中垂线上。
BC的中垂线为y = (3-1)/2 = 1
AB的方程为x/4 + y/3 = 1(截距式)
二者联立，可得P的坐标为(8/3, 1)
(2) 直线l与X轴所夹的锐角a=45° 已知圆x^2+y^2+x-6y+m=0与直线x+2y-3=0相交解：圆的方程x² +y² +x-6y+m=0可化为：(x+1/2)² +(y-3)² =37/4 -m
则设圆的圆心为C(-1/2,3)，半径r=√(37/4 -m)
作线段PQ中点M，连结 已知直角坐标平面上点Q（2，0）和圆C：X2+Y设M的坐标是(x,y)，
|MC|^2=x^2+y^2
设动点M到圆的切线长为d
d^2=|MC|^2-r^2=x^2+y^2-1
|MQ|^2=(x-2)^2+y^2
当d/MQ=1时，d=MQ，即d^2=|MQ|^2
则：x^2+y^2-1=(x-2 已知M为圆C：x2+y2-4x-14y+45=0上任一点，且（Ⅰ）由点P（a，a+1）在圆C上，
可得a2+（a+1）2-4a-14（a+1）+45=0，所以a=4，P（4，5）．
所以|PQ|＝(4+2)2+(5?3)2＝210，KPQ＝3?5?2?4＝13．（6分）
（Ⅱ）由C：x2+ 与直线x+y-2=0和曲线x^2+y^2-12x-12y+54=0都圆c:x^2+y^2-12x-12y+54=0,(x-6)^2+(y-6)^2=18
c(6,6),R=3√2
c到x+y-2=0的距离：h=5√2
所求圆的园心在过c与x+y-2=0垂直的直线L上,直径d=5√2-3√2=2√2，半径r=√2
L 已知三角形ABC的三个顶点A（0，0）B（4，8）AM=3MB,由定比分点公式（高一向量部分的内容），得到M坐标为（3，6）。ABC面积=2AMN面积，而AM=3MB，说明AN=2/3AC,N点坐标为（4，-8/3）MN的直线方程就可以求了 已知定点A(2,0),Q是曲线C:x2+y2=1上的动点，A(2,0),Q是曲线C:x2+y2=1上的动点，M为AQ的中点
设M(x,y),则
2x=xA+xQ=2+xQ
2y=yA+yQ=0+yQ
(xQ)^2+(yQ)^2=1
(2x-2)^2+(2y)^2=1DeepDyve requires Javascript to function. Please enable Javascript on your browser to continue.
Serum interferon‐inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B
, Volume 43 (1)
Serum interferon-inducible protein 10 levels predict hepatitis Bs antigen seroclearance in patients with chronic hepatitis BG. L.-H. Wong*,+,?, H. L.-Y. Chan*,+,?, H.-Y. Chan*,+,?, C.-H. Tse*,+,?, A. M.-L. Chim*,+, A. O.-S. Lo*,+& V. W.-S. Wong*,+,?*Institute of Digestive Disease, TheChinese University of Hong Kong,Hong Kong.+Department of Medicine andTherapeutics, The Chinese Universityof Hong Kong, Hong Kong.?State Key Laboratory of DigestiveDisease, The Chinese University ofHong Kong, Hong Kong.Correspondence to:Dr V. W. S. Wong, Department ofMedicine and Therapeutics, TheChinese University of Hong Kong, 9/FPrince of Wales Hospital, 30-32 NganShing Street, Shatin, Hong Kong.E-mail: wongv@cuhk.edu.hkPublication dataSubmitted 6 August 2015First decision 8 September 2015Resubmitted 10 September 2015Accepted 6 October 2015EV Pub Online 3 November 2015This article was accepted for publicationafter full peer-review.SUMMARYBackgroundHepatitis B s antigen (HBsAg) seroclearance is regarded as the optimalvirological end-point.AimTo investigate the dynamic changes in serum cytokine levels around thetime of HBsAg seroclearance.MethodsThis was a case–control study. Consecutive patients with chronic hepatitisB (CHB) who lost HBsAg were matched with those remained positive forHBsAg with same age, gender, HBeAg status and presence of cirrhosis in1:2 ratio. Relevant serum cytokines [interleukin (IL)-2, IL-3, IL-4, IL-7, IL-9, IL-10, IL-12, IL-15, IL-21 interferon-c, tumour necrosis factor-a (TNF-a), granulocyte macrophage colony-stimulating factor (GM-CSF) and inter-feron-inducible protein 10 (IP-10)] were assayed at the time (Year 0) and3 years before (Year ?3) HBsAg seroclearance.ResultsSeventy-one and 142 CHB patients who did and did not achieve HBsAg sero-clearance were included. Mean age was 48 AE 11
76% were male, 20%had positive HBeAg, 99 (46%) patients received anti-viral therapy, and meanbaseline HBV DNA was 3.78 AE 2.28 log IU/mL vs. 4.36 AE 2.13 log IU/mLrespectively (P = 0.05). In those who achieved HBsAg seroclearance, serumIL-15 and GM-CSF levels decreased significantly from Year ?3 to Year 0(P = 0.017 and 0.05 respectively). When compared to controls, only serumIP-10 level was significantly lower at Year 0 than at Year ?3 in patients withHBsAg seroclearance. Lower serum IP-10 level at Year 0 was the only factorassociated with HBsAg seroclearance. There was no correlation betweenserum IP-10 and HBsAg levels around the time of HBsAg seroclearance.ConclusionLower serum IP-10 level at Year 0 was the only factor associated withHBsAg seroclearance.Aliment Pharmacol Ther 2016; 43: 145–153? 2015 John Wiley & Sons Ltd 145doi:10.1111/apt.13447Alimentary Pharmacology and Therapeutics
Loading next page...
System error. Please try again!
The text was blurry
Page doesn't load
Include any more information that will help us locate the issue and fix it faster for you.
Submit report
/lp/wiley/serum-interferon-inducible-protein-10-levels-predict-hepatitis-b-s-X8gAntgUwr
Copyright (C) 2016 John Wiley & Sons Ltd
10.1111/apt.13447
Publisher site
Summary Background Hepatitis B s antigen (HBsAg) seroclearance is regarded as the optimal virological end‐point. Aim To investigate the dynamic changes in serum cytokine levels around the time of HBsAg seroclearance. Methods This was a case&control study. Consecutive patients with chronic hepatitis B (CHB) who lost HBsAg were matched with those remained positive for HBsAg with same age, gender, HBeAg status and presence of cirrhosis in 1:2 ratio. Relevant serum cytokines (interleukin (IL)‐2, IL‐3, IL‐4, IL‐7, IL‐9, IL‐10, IL‐12, IL‐15, IL‐21 interferon‐&, tumour necrosis factor‐& (TNF‐&), granulocyte macrophage colony‐stimulating factor (GM‐CSF) and interferon‐inducible protein 10 (IP‐10)) were assayed at the time (Year 0) and 3 years before (Year &3) HBsAg seroclearance. Results Seventy‐one and 142 CHB patients who did and did not achieve HBsAg seroclearance were included. Mean age was 48 & 11 76% were male, 20% had positive HBeAg, 99 (46%) patients received anti‐viral therapy, and mean baseline HBV DNA was 3.78 & 2.28 log IU/mL vs. 4.36 & 2.13 log IU/mL respectively (P = 0.05). In those who achieved HBsAg seroclearance, serum IL‐15 and GM‐CSF levels decreased significantly from Year &3 to Year 0 (P = 0.017 and 0.05 respectively). When compared to controls, only serum IP‐10 level was significantly lower at Year 0 than at Year &3 in patients with HBsAg seroclearance. Lower serum IP‐10 level at Year 0 was the only factor associated with HBsAg seroclearance. There was no correlation between serum IP‐10 and HBsAg levels around the time of HBsAg seroclearance. Conclusion Lower serum IP‐10 level at Year 0 was the only factor associated with HBsAg seroclearance.
Alimentary Pharmacology & Therapeutics
Published:
Recommended Articles
Loading...
References
Hepatitis B virus infection
Trepo, T Chan, C Lok, Lok
EASL clinical practice guidelines: management of chronic hepatitis B virus infection
Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Liaw, L Kao, K Piratvisuth, Piratvisuth
Long‐ erm clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance
Ahn, A Park, P Park, Park
Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma
Liu, L Yang, Y Lee, Lee
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
Kim, K Lim, L An, An
Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues
Wong, W Chan, C Lo, Lo
Cytokines in viral hepatitis
Koziel, Koziel
Changes of HBsAg and interferon‐inducible protein 10 serum levels in naive HBeAg‐
egative chronic hepatitis B patients under 4‐year entecavir therapy
Papatheodoridis, P Goulis, G Manolakopoulos, Manolakopoulos
High serum IL‐21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B
Ma, Ma; Huang, H Li, Li
Serum levels of interferon‐gamma‐inducible protein 10 and response to peginterferon therapy in HBeAg‐positive chronic hepatitis B
Sonneveld, S Arends, A Boonstra, B Hansen, H Janssen, Janssen
Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma
Chan, C Hui, H Wong, Wong
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon‐alpha2b and lamivudine with lamivudine alone
Chan, C Leung, L Hui, Hui
Transient elastography: kill two birds with one stone?
Wong, Wong
Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation
Chan, C Chui, C Lau, Lau
Hepatitis B surface antigen quantification: why and how to use it in 2011 – a core group report
Chan, C Thompson, T Martinot‐Peignoux, Martinot‐Peignoux
Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers
Wong, W Chan, C Mo, Mo
IFN‐gamma‐inducible protein 10 (IP‐10; CXCL10)‐deficient mice reveal a role for IP‐10 in effector T cell generation and trafficking
Dufour, D Dziejman, D Liu, L Leung, L Lane, L Luster, Luster
Development of TH1 CD4 + T cells through IL‐12 produced by Listeria‐induced macrophages
Hsieh, H Macatonia, M Tripp, T Wolf, W O'Garra, O'G Murphy, Murphy
Essential role of IL‐21 in B cell activation, expansion, and plasma cell generation during CD4 + T cell‐B cell collaboration
Kuchen, K Robbins, R Sims, Sims
Interleukin‐10 and related cytokines and receptors
Pestka, P Krause, K Sarkar, S Walter, W Shi, S Fisher, Fisher
Serum interleukin 9 level as a predictve marker of spontaneous seroclearance of hepatitis B surface antigen in chronic hepatitis B patients
Yang, Y Lee, L Chien, Chien
Rapid downregulation of programmed death‐1 and interferon‐gamma‐inducible protein‐10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B
Hou, H Wu, Wu; Wang, Wang
Relationship between the expression of IP‐10 and IP‐10 mRNA in peripheral blood and HBV DNA level in patients with cirrhosis
Wang, W Wang, W Xiang, X Hu, Hu
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C
Butera, B Marukian, M Iwamaye, Iwamaye
Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection
Larrubia, L Benito‐Martinez, Benito‐M Calvino, C Sanz‐de‐Villalobos, Sanz‐de‐V Parra‐Cid, Parra‐Cid
The role of CCR5/CXCR3 expressing CD8 + cells in liver damage and viral control during persistent hepatitis C virus infection
Larrubia, L Calvino, C Benito, Benito
Blocking chemokine responsive to gamma‐2/interferon (IFN)‐gamma inducible protein and monokine induced by IFN‐gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus‐specific cytotoxic T lymphocytes
Kakimi, K Lane, L Wieland, Wieland
You&re reading a free preview. Subscribe to read the entire article.
DeepDyve is your
personal research library
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Your journals are on DeepDyve
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
&Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.&Daniel C.
It’s like Spotify but for academic articles.&
@Phil_Robichaud
&I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.&
&My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.&
@JoseServera
DeepDyveFreelancer</h3DeepDyveProPriceFREE$49/month $360/yearSave searches fromGoogle Scholar,PubMedCreate lists toorganize your researchExport lists, citationsRead DeepDyve articlesAbstract access onlyUnlimited access to over18 million full-text articlesPrint20 pages / monthPDF Discount20% off
System error. Please try again!
Create Account
By signing up, you agree to DeepDyve&s
Already have an account?
Bookmark this article. You can see your Bookmarks on your .
To save an article,
for a DeepDyve account if you don&t already have one.
To subscribe to email alerts, please
for a DeepDyve account if you don&t already have one.
To get new article updates from a journal on your personalized homepage, please
for a DeepDyve account if you don&t already have one.WE‐SAM‐201B‐2: SPECT/CT: Basics, Quality Assurance, and Clinical Applications
Single‐photon emission computed tomography (SPECT) together with computed tomography (CT), commonly referred to as SPECT/CT, is rapidly becoming a mainstream imaging modality and creating a new paradigm for SPECT imaging. The ability to contemporaneously acquire electro‐mechanically registered dual‐modality SPECT and CT scans improves the SPECT image quality due to CT‐ased attenuation correction and enhances the diagnostic confidence of SPECT by providing a CT‐ased anatomical overlay. The utilization of SPECT/CT has been mainly in the field of oncology with applications including: tumor localization, differential diagnosis, staging and response to treatment, pre‐surgical planning, radiation therapy treatment planning, and quantitative SPECT/CT‐ased internal radionuclide therapy dosimetry/treatment planning. SPECT/CT is also being utilized for cardiac and skeletal imaging and imaging of other non‐malignant diseases.This lecture will review the physics principles underlying SPECT and SPECT/CT imaging, discuss quality assurance of SPECT/CT systems, and present several examples of the clinical application of SPECT/CT.Learning Objectives:1. To understand the physics principles underlying SPECT/CT image acquisition, processing and reconstruction2. To understand the quality assurance procedures specific to hybrid SPECT/CT system3. To become familiar with clinical applications of SPECT/CT imagingDo you want to read the rest of this article?Request full-text
This research doesn&#x27;t cite any other publications.ArticleNovember 2011 · The purpose of this study was to evaluate the effects of voxel size and iterative reconstruction parameters on the radial and tangential resolution for 99mTc SPECT as a function of radial distance from isocenter. SPECT/CT scans of eight coplanar point sources of size smaller than 1 mm3 containing high concentration 99mTc solution were acquired on a SPECT/CT system with 5/8 inch NaI(Tl)... [Show full abstract]ArticleJune 2015 · There have been significant recent advances in SPECT/CT and PET/CT for Oncology and Cardiology. In oncologic imaging, some commercial SPECT/CT systems now output quanti calibration and calculation of these quantitative uptake values will be discussed. Advances in PET detector design and PET data acquisition modes that have implemented in commercial PET/CT systems will be... [Show full abstract]ArticleJune 2015 · Yttrium-90 (Y90) microsphere therapy, a form of radiation therapy, is an increasingly popular option for care of patients with liver metastases or unresectable hepatocellular carcinoma. The therapy directly delivers Y90 microspheres via the hepatic artery to disease sites. Following delivery, a vast majority of microspheres preferentially lodge in the capillary vessels due to their embolic... [Show full abstract]ArticleApril 2014 · This paper evaluates the effects of computed tomography (CT) image noise and artifacts on quantitative single-photon emission computed-tomography (SPECT) imaging, with the aim of establishing an appropriate range of CT acquisition parameters for low-dose protocols with respect to accurate SPECT attenuation correction (AC).
SPECT images of two geometric and one anthropomorphic phantom were... [Show full abstract]